Curia, the former AMRI,  to Acquire Integrity Bio, Expanding Its Biologic Formulation and Fill-Finish Capabilities

One day after announcing its name change to Curia, leading contract research, development and manufacturing organization AMRI reported it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held  biologics formulation and fill-finish organization headquartered in Camarillo, California.

Integrity Bio is expert in hard-to-formulate biologics and in fill-finish for Phase 1/2 clinical trials, including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form.

Their customers range from small virtual startups to global Fortune 500 companies .

Integrity Bio’s biologic capabilities are complementary with Curia’s existing business.

  • Curia currently provides customers with integrated solutions for small molecule drugs from formulation development through fill-finish commercial manufacturing across facilities in Albuquerque; Burlington, Massachusetts and Glasgow, Scotland.
  • Also adds West Coast coverage to Curia’s East Coast and European capabilities.

This transaction reflects the growth strategy embodied in the name change. It is expected to close in the third quarter. Terms of the agreement were not disclosed.